A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine

Jeong Heo, Jun Yong Park, Heon Ju Lee, Won Young Tak, Soon Ho Um, Do Young Kim, Ki Tae Yoon, Soo Young Park, Yeon Seok Seo, Kwang Hyub Han, Mong Cho, Sang Hoon Ahn

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Growing numbers of chronic hepatitis B (CHB) patients in the Asia-Pacific region have failed first-line therapy with low genetic barrier drugs. This prospective, 96-week study investigated the antiviral efficacy, safety and tolerability of switching to entecavir versus maintaining lamivudine in CHB patients with a partial virological response to lamivudine. Methods: A total of 72 hepatitis B e antigen (HBeAg)-positive patients, with serum HBV DNA≥60 IU/ml after ≥6 months lamivudine monotherapy were randomized 1:1 to receive either entecavir 1.0 mg/day, or continued lamivudine 100 mg/day. Results: Mean duration of prior lamivudine treatment was 15.1 months in the lamivudine-maintained patients and 16.1 months in the entecavir-switch patients, with mean baseline HBV DNA levels of 4.66 and 4.55 log10 IU/ml, respectively. A greater proportion of entecavir-switch than lamivudine- maintained patients achieved undetectable HBV DNA at all time points (67.6% versus 11.4% at week 96; P<0.001). Entecavir-switch patients achieved a greater mean decrease in HBV DNA level by week 4, maintained through week 96. Entecavir-switch patients with baseline HBV DNA<5 log10 IU/ml were more likely to achieve a virological response at week 96. A total of 6 (17.6%) entecavir-switch and 2 (5.7%) lamivudine-maintained patients achieved HBeAg loss, and 3 (8.8%) entecavir and 1 (2.9%) lamivudine patients achieved HBeAg seroconversion. Genotypic resistance to the assigned intervention emerged in 82.9% (29/35) of lamivudine-maintained patients, and in 3% (1/34) of entecavir-switch patients after 96 weeks. Conclusions: Switching to entecavir in patients with a partial virological response to lamivudine resulted in increased virological efficacy and lower rates of antiviral resistance than maintaining lamivudine.

Original languageEnglish
Pages (from-to)1563-1570
Number of pages8
JournalAntiviral therapy
Volume17
Issue number8
DOIs
Publication statusPublished - 2012 Dec 1

Fingerprint

Lamivudine
Chronic Hepatitis B
Hepatitis B e Antigens
DNA
entecavir
Antiviral Agents

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Heo, Jeong ; Park, Jun Yong ; Lee, Heon Ju ; Tak, Won Young ; Um, Soon Ho ; Kim, Do Young ; Yoon, Ki Tae ; Park, Soo Young ; Seo, Yeon Seok ; Han, Kwang Hyub ; Cho, Mong ; Ahn, Sang Hoon. / A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine. In: Antiviral therapy. 2012 ; Vol. 17, No. 8. pp. 1563-1570.
@article{7d8f66e202814cde86087b236f380396,
title = "A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine",
abstract = "Background: Growing numbers of chronic hepatitis B (CHB) patients in the Asia-Pacific region have failed first-line therapy with low genetic barrier drugs. This prospective, 96-week study investigated the antiviral efficacy, safety and tolerability of switching to entecavir versus maintaining lamivudine in CHB patients with a partial virological response to lamivudine. Methods: A total of 72 hepatitis B e antigen (HBeAg)-positive patients, with serum HBV DNA≥60 IU/ml after ≥6 months lamivudine monotherapy were randomized 1:1 to receive either entecavir 1.0 mg/day, or continued lamivudine 100 mg/day. Results: Mean duration of prior lamivudine treatment was 15.1 months in the lamivudine-maintained patients and 16.1 months in the entecavir-switch patients, with mean baseline HBV DNA levels of 4.66 and 4.55 log10 IU/ml, respectively. A greater proportion of entecavir-switch than lamivudine- maintained patients achieved undetectable HBV DNA at all time points (67.6{\%} versus 11.4{\%} at week 96; P<0.001). Entecavir-switch patients achieved a greater mean decrease in HBV DNA level by week 4, maintained through week 96. Entecavir-switch patients with baseline HBV DNA<5 log10 IU/ml were more likely to achieve a virological response at week 96. A total of 6 (17.6{\%}) entecavir-switch and 2 (5.7{\%}) lamivudine-maintained patients achieved HBeAg loss, and 3 (8.8{\%}) entecavir and 1 (2.9{\%}) lamivudine patients achieved HBeAg seroconversion. Genotypic resistance to the assigned intervention emerged in 82.9{\%} (29/35) of lamivudine-maintained patients, and in 3{\%} (1/34) of entecavir-switch patients after 96 weeks. Conclusions: Switching to entecavir in patients with a partial virological response to lamivudine resulted in increased virological efficacy and lower rates of antiviral resistance than maintaining lamivudine.",
author = "Jeong Heo and Park, {Jun Yong} and Lee, {Heon Ju} and Tak, {Won Young} and Um, {Soon Ho} and Kim, {Do Young} and Yoon, {Ki Tae} and Park, {Soo Young} and Seo, {Yeon Seok} and Han, {Kwang Hyub} and Mong Cho and Ahn, {Sang Hoon}",
year = "2012",
month = "12",
day = "1",
doi = "10.3851/IMP2277",
language = "English",
volume = "17",
pages = "1563--1570",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "8",

}

A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine. / Heo, Jeong; Park, Jun Yong; Lee, Heon Ju; Tak, Won Young; Um, Soon Ho; Kim, Do Young; Yoon, Ki Tae; Park, Soo Young; Seo, Yeon Seok; Han, Kwang Hyub; Cho, Mong; Ahn, Sang Hoon.

In: Antiviral therapy, Vol. 17, No. 8, 01.12.2012, p. 1563-1570.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine

AU - Heo, Jeong

AU - Park, Jun Yong

AU - Lee, Heon Ju

AU - Tak, Won Young

AU - Um, Soon Ho

AU - Kim, Do Young

AU - Yoon, Ki Tae

AU - Park, Soo Young

AU - Seo, Yeon Seok

AU - Han, Kwang Hyub

AU - Cho, Mong

AU - Ahn, Sang Hoon

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Background: Growing numbers of chronic hepatitis B (CHB) patients in the Asia-Pacific region have failed first-line therapy with low genetic barrier drugs. This prospective, 96-week study investigated the antiviral efficacy, safety and tolerability of switching to entecavir versus maintaining lamivudine in CHB patients with a partial virological response to lamivudine. Methods: A total of 72 hepatitis B e antigen (HBeAg)-positive patients, with serum HBV DNA≥60 IU/ml after ≥6 months lamivudine monotherapy were randomized 1:1 to receive either entecavir 1.0 mg/day, or continued lamivudine 100 mg/day. Results: Mean duration of prior lamivudine treatment was 15.1 months in the lamivudine-maintained patients and 16.1 months in the entecavir-switch patients, with mean baseline HBV DNA levels of 4.66 and 4.55 log10 IU/ml, respectively. A greater proportion of entecavir-switch than lamivudine- maintained patients achieved undetectable HBV DNA at all time points (67.6% versus 11.4% at week 96; P<0.001). Entecavir-switch patients achieved a greater mean decrease in HBV DNA level by week 4, maintained through week 96. Entecavir-switch patients with baseline HBV DNA<5 log10 IU/ml were more likely to achieve a virological response at week 96. A total of 6 (17.6%) entecavir-switch and 2 (5.7%) lamivudine-maintained patients achieved HBeAg loss, and 3 (8.8%) entecavir and 1 (2.9%) lamivudine patients achieved HBeAg seroconversion. Genotypic resistance to the assigned intervention emerged in 82.9% (29/35) of lamivudine-maintained patients, and in 3% (1/34) of entecavir-switch patients after 96 weeks. Conclusions: Switching to entecavir in patients with a partial virological response to lamivudine resulted in increased virological efficacy and lower rates of antiviral resistance than maintaining lamivudine.

AB - Background: Growing numbers of chronic hepatitis B (CHB) patients in the Asia-Pacific region have failed first-line therapy with low genetic barrier drugs. This prospective, 96-week study investigated the antiviral efficacy, safety and tolerability of switching to entecavir versus maintaining lamivudine in CHB patients with a partial virological response to lamivudine. Methods: A total of 72 hepatitis B e antigen (HBeAg)-positive patients, with serum HBV DNA≥60 IU/ml after ≥6 months lamivudine monotherapy were randomized 1:1 to receive either entecavir 1.0 mg/day, or continued lamivudine 100 mg/day. Results: Mean duration of prior lamivudine treatment was 15.1 months in the lamivudine-maintained patients and 16.1 months in the entecavir-switch patients, with mean baseline HBV DNA levels of 4.66 and 4.55 log10 IU/ml, respectively. A greater proportion of entecavir-switch than lamivudine- maintained patients achieved undetectable HBV DNA at all time points (67.6% versus 11.4% at week 96; P<0.001). Entecavir-switch patients achieved a greater mean decrease in HBV DNA level by week 4, maintained through week 96. Entecavir-switch patients with baseline HBV DNA<5 log10 IU/ml were more likely to achieve a virological response at week 96. A total of 6 (17.6%) entecavir-switch and 2 (5.7%) lamivudine-maintained patients achieved HBeAg loss, and 3 (8.8%) entecavir and 1 (2.9%) lamivudine patients achieved HBeAg seroconversion. Genotypic resistance to the assigned intervention emerged in 82.9% (29/35) of lamivudine-maintained patients, and in 3% (1/34) of entecavir-switch patients after 96 weeks. Conclusions: Switching to entecavir in patients with a partial virological response to lamivudine resulted in increased virological efficacy and lower rates of antiviral resistance than maintaining lamivudine.

UR - http://www.scopus.com/inward/record.url?scp=84871894884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871894884&partnerID=8YFLogxK

U2 - 10.3851/IMP2277

DO - 10.3851/IMP2277

M3 - Article

C2 - 22872647

AN - SCOPUS:84871894884

VL - 17

SP - 1563

EP - 1570

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 8

ER -